NEW YORK, July 21, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Thermo Fisher Scientific Inc. (NYSE: TMO),
Quest Diagnostics Inc. (NYSE: DGX), Exact Sciences Corporation
(NASDAQ: EXAS), VWR Corporation (NASDAQ: VWR), and Bio-Reference
Laboratories Inc. (NASDAQ: BRLI). Free research report on Thermo
Fisher Scientific can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=TMO On
Monday, July 20, 2015, the NASDAQ
Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial
Average advanced 0.08%, to finish the day at 18,100.41, and the
S&P 500 closed at 2,128.28, up 0.08%. The losses were broad
based as five out of nine sectors ended the session in negative.
Register for your complimentary reports at the links given below.
Thermo Fisher Scientific Inc.'s stock edged 0.31% higher, to
close the day at $136.17. The stock
recorded a trading volume of 1.05 million shares, below its three
months average volume of 1.65 million shares. Over the last one
month and over the past three months, Thermo Fisher Scientific
Inc.'s shares have gained 5.00% and 1.71%, respectively.
Furthermore, the stock has advanced 8.94% since the start of this
year. The company's shares are trading 4.33% above their 50-day
moving average and 7.23% above their 200-day moving average.
Additionally, Thermo Fisher Scientific Inc. traded at a PE ratio of
31.59 and has a Relative Strength Index (RSI) of 62.48. Sign up and
read the free notes on TMO at:
https://www.EquityResearchInstitute.com/reports?keyword=TMO
On Monday, shares in Quest Diagnostics Inc. recorded a trading
volume of 0.78 million shares, lower than their three months
average volume of 1.53 million shares. The stock ended the day
0.23% lower at $73.09. Shares of the
company traded at a PE ratio of 21.06. Although, Quest Diagnostics
Inc.'s stock has lost 3.51% in the previous three months, it has
advanced 0.85% in the last one month and 10.65% on YTD basis. The
company is trading above its 50-day and 200-day moving averages by
0.41% and 5.99%, respectively. Furthermore, shares of Quest
Diagnostics Inc. have an RSI of 52.25. The complimentary notes on
DGX can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=DGX
Exact Sciences Corp.'s stock lost 2.10%, to close Monday's
session at $27.03. The stock recorded
a trading volume of 1.78 million shares, above its three months
average volume of 1.46 million shares. Over the last one month and
since the start of this year, Exact Sciences Corp.'s shares have
lost 3.88% and 1.49%, respectively. However, the stock has gained
17.57% in the previous three months. The company is trading 7.62%
above its 200-day moving average. Furthermore, Exact Sciences
Corp.'s stock has an RSI of 43.42. Register for free on Equity
Research Institute and access the latest research on EXAS at:
https://www.EquityResearchInstitute.com/reports?keyword=EXAS
VWR Corp.'s stock finished Monday's session 0.57% higher at
$26.30. A total of 0.34 million
shares were traded, which was below its three months average volume
of 0.62 million shares. Over the last one month and since the
beginning of 2015, VWR Corp.'s shares have gained 0.77% and 1.66%,
respectively. However, the stock has lost 4.50% in the previous
three months. The company's shares are trading above their 200-day
moving average by 4.36%. VWR Corp.'s stock traded at a PE ratio of
18.26 and has an RSI of 49.00. The complete research on VWR is
available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=VWR
On Monday, shares in Bio-Reference Laboratories Inc. ended the
session 1.45% lower at $44.31. The
stock reported a trading volume of 0.40 million shares, below its
three months average volume of 0.59 million shares. Shares of the
company traded at a PE ratio of 24.35. Bio-Reference Laboratories
Inc.'s shares have surged 11.11% in the last one month, 27.07% in
the previous three months and 37.91% on YTD basis. The company is
trading 15.53% above its 50-day moving average and 32.33% above its
200-day moving average. Moreover, shares of Bio-Reference
Laboratories Inc. have an RSI of 67.01. Free in-depth research on
BRLI is available at:
https://www.EquityResearchInstitute.com/reports?keyword=BRLI
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com